Biologic heroes: Are you keeping up with the rapidly evolving treatment landscape for paediatric psoriasis
Explore the key highlights from this symposium in May 2021, addressing current unmet medical needs in paediatric psoriasis. Our expert panel offer up-to-date insight into recent and ongoing research into the safety and efficacy of biologic agents. The symposium offers clinicians thorough understanding of therapeutic developments, and insights which could improve patients’ chances of reaching more ambitious treatment targets.
Professor Amy Paller explores the extent to which new treatments are addressing unmet needs in paediatric psoriasis. She considers quality of life indicators impacted by paediatric psoriasis and discusses how the improved understanding of treatment may contribute to prevention of a ‘psoriatic march’.
In this video Professor Paller provides detail related to the importance of predicting the course of the condition and avoiding potential co-morbidities.
Professor Paller discusses guideline recommendations and considers the changing landscape of biologic treatments. She highlights the potential for biologics achieving PASI 90 and PASI 100 in the majority of patients and the associated impact on improving quality of life.
Professor Matthias Augustin discusses differentiation of emerging approved biologic treatments for paediatric psoriasis. He touches on the cumulative burden of skin disease and emphasises the importance of preventing irreversible skin damage through early intervention. He discusses that real-world evidence and RCTs are both essential for clinical decisions, management and economics.
In the video below, Professor Augustin discusses the complexities behind the treatment selection process considering clinical criteria, drug characteristics, patient characteristics and label and legal considerations.
Professor Augustin considers the efficacy and safety of specific biologic treatments based on currently available evidence.
Professor Augustin explores the most recent data from AAD VMX 2021 and considers the effectiveness and safety of secukinumab and ixekizumab in moderate-to-severe paediatric psoriasis.
Professor Marieke Seyger considers achieving long-term clearance in paediatric psoriasis. In the video below, she discusses when systemic treatment should be initiated, providing detail of the results from the Child-CAPTURE registry and considers data underpinning the question of when to initiate systemic treatment in paediatric patients.
Professor Seyger looks to the association between the Psoriasis Area Severity Index (PASI) and quality of life in children and goes on to consider differences in quality-of-life improvements dependent upon the type of treatment used to treat paediatric psoriasis.
In the video below, Professor Seyger discusses the importance of effective communication to support parents caring for children with psoriasis, emphasises interactive consulting. and offers insight by sharing data from her own clinical practice.
In the video below, Professor Seyger discusses the importance of effective communication to support parents caring for children with psoriasis, emphasising interactive consulting and offering insight into data from her own clinical practice.
This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.